Tango Therapeutics

Tango Therapeutics

TNGX· Manufacturing· Fiscal year ends in December

No proxy on file names the CEO of Tango Therapeutics.

Executives3

See all
  1. 1Barbara Weber, M.D.FY2025
  2. 2Adam Crystal, M.D., Ph.D.FY2025
  3. 3Daniella BeckmanFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Tango Therapeutics paid its 3 named executives $5.7M in total in FY2025 (Dec).

Name
Barbara Weber, M.D.Executive Chairman
Adam Crystal, M.D., Ph.D.President of Research and Development
Daniella BeckmanFormer Chief Financial Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers18

See all

The FY2025 (Dec) proxy of Tango Therapeutics names 18 peer companies for pay. Among Tango Therapeutics and these peers, CEO pay was 7th highest of 8.

7th highest of 8in Tango Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$2.5M$9.5M

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board2

See all
  • Lesley Ann CalhounDirector · 4 yr on the boardIndependentAudit (Chair), Nominating and Corporate Governance—Paid as an executive
  • Sung LeeDirector · -1 yr on the boardIndependentAudit—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. PayDEF 14A
  2. PayDEF 14A
  3. PayDEF 14A
  4. PayDEF 14A
  5. Board3
  6. PayDEF 14A
  7. PayDEF 14A
  8. PayDEF 14A
  9. PayDEF 14A
  10. PayDEF 14A

Filings6

See all
Proxy statementDEF 14AApr 17, 2026FY2025
Annual report10-KMar 5, 2026FY2025
Proxy statementDEF 14AApr 21, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 29, 2024FY2023
Annual report10-KMar 18, 2024FY2023